Sildenafil Tablet
Product Images NDC 68788-7974

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68788-7974). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Sildenafil Figure 1)

Figure1 (Sildenafil Figure 1)
A line graph depicting estimated cumulative mortality rate (%) over a 5-year period for three different dose groups labeled High Dose, Medium Dose, and Low Dose. The graph includes a timeline from 0 to 5 years on the horizontal axis and cumulative mortality rate percentage on the vertical axis, along with the number of subjects at risk over time for each group.*
FDA Label Image

Sildenafil_fig2 (Sildenafil Figure 2)

Sildenafil_fig2 (Sildenafil Figure 2)
A forest plot chart illustrating fold change and 90% confidence intervals of sildenafil's pharmacokinetics parameters (AUC and Cmax) when co-administered with various interacting drugs. The chart includes drugs like Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir, along with dosing recommendations for each interaction, such as no dose adjustment or contraindication. The horizontal axis shows relative change on a logarithmic scale.*
FDA Label Image

Figure3 (Sildenafil Figure 3)

Figure3 (Sildenafil Figure 3)
A chart showing fold change and 90% confidence intervals for various interacting drugs with parameters such as AUC, Cmax, and INR. Each drug is listed with a corresponding recommendation, mostly indicating no dose adjustment except for Ritonavir, which recommends against coadministration.*
FDA Label Image

Figure4 (Sildenafil Figure 4)

Figure4 (Sildenafil Figure 4)
A line graph depicting changes from baseline in meters over a 12-week study period for Sildenafil tablets. The x-axis represents weeks 4, 8, and 12, while the y-axis indicates change from baseline in meters. Four groups shown include Placebo, Sildenafil 20 mg TID, Sildenafil 40 mg TID, and Sildenafil 80 mg TID, with data points and error bars illustrating response trends over time.*
FDA Label Image

Figure5 (Sildenafil Figure 5)

Figure5 (Sildenafil Figure 5)
A forest plot chart depicting placebo-corrected changes in 6-minute walk distance (meters) comparing Sildenafil 20 mg TID to placebo. The chart shows subgroup analyses by baseline walk distance, etiology, pulmonary hypertension classification, gender, age, mean PAP, and PVRI. Each subgroup displays the number of subjects and corresponding point estimates with 95% confidence intervals.*
FDA Label Image

Figure6 (Sildenafil Figure 6)

Figure6 (Sildenafil Figure 6)
A Kaplan-Meier curve chart showing the percentage of patients without clinically worsening over days from randomization, comparing Sildenafil versus Placebo. The graph tracks data over approximately 112 days, with Sildenafil indicated by a dashed line and Placebo by a solid line.*
FDA Label Image

Sildenafil-figure-7 (Sildenafil Figure 7)

Sildenafil-figure-7 (Sildenafil Figure 7)
A line plot showing the mean change from baseline in meters with standard error bars for Sildenafil oral tablets at 1 mg, 5 mg, and 20 mg doses administered three times daily (TID). Data points are displayed for weeks 4, 8, and 12, illustrating comparative treatment effects over time.*
FDA Label Image

Structure (Sildenafil Structure)

Structure (Sildenafil Structure)
Chemical structure of Sildenafil, showing the detailed molecular arrangement of atoms including nitrogen, oxygen, and sulfur atoms characteristic to the compound.*
FDA Label Image

Sildenafil Tablets 20mg (Sildenafil 20mg)

Sildenafil Tablets 20mg (Sildenafil 20mg)
Sildenafil Tablets 20 mg label with dosage instructions in English and Spanish. The label states the product is generic for Revatio, containing sildenafil citrate equivalent to 20 mg sildenafil per tablet. Manufacturer information is Ajanta Pharma USA Inc. and Preferred Pharmaceuticals Inc. logo is visible. The label includes storage instructions and federal caution regarding drug transfer.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.